CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

nintedanib

Last Updated: October 16, 2020
Result type: Reports
Project Number: SR0654-000
Product Line: Common Drug Review

Generic Name: nintedanib

Brand Name: Ofev

Manufacturer: Boehringer Ingelheim (Canada) Ltd.

Indications: chronic fibrosing interstitial lung diseases

Manufacturer Requested Reimbursement Criteria1: As per the Health Canada approved indication for progressive fibrosing-ILD (PF-ILD).

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open June 25, 2020
Call for patient input closed August 17, 2020
Clarification:

- Patient input submission received from British Columbia Lung Association & Lung Groups, Canadian Pulmonary Fibrosis Foundation and The Ontario Lung Association / Lung Health Foundation

Submission received July 24, 2020
Submission accepted August 13, 2020
Clarification:

- Submission was not accepted for review on 10 Aug 2020

Review initiated August 14, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for comment November 10, 2020
Deadline for sponsors comments November 19, 2020
CADTH responses on draft review report(s) provided to sponsor January 08, 2021
Expert committee meeting (initial) January 20, 2021
Draft recommendation issued February 01, 2021
To
February 03, 2021